Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
| ▸ | CFB | P00751 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1157462 | 0.91 | KCNA5 (0.35) | KCNA5CFBBACE1RPS6KB1AKT1 | |
| SCHEMBL1157415 | 0.90 | CFB (0.37) | CFBP2RX7ADRA2AADRA1A | |
| SCHEMBL1157181 | 0.90 | CFB (0.33) | CFBP2RX7ADRA2AADRA2BADRA2C | |
| SCHEMBL1156876 | 0.90 | KCNA5 (0.35) | KCNA5CFBBACE1RPS6KB1AKT1 | |
| SCHEMBL13771783 | 0.90 | CFB (0.35) | KCNA5CFBBACE1RPS6KB1ADRA2A | |
| SCHEMBL1157104 | 0.90 | CFB (0.33) | CFBP2RX7RPS6KB1AKT1AURKB | |
| SCHEMBL13771777 | 0.87 | KCNA5 (0.33) | KCNA5CFBRPS6KB1AURKA | |
| SCHEMBL3415101 | 0.84 | CFB (0.34) | CFBGMNNCYP1A2CYP3A4HTR1A | |
| SCHEMBL3433520 | 0.84 | CFB (0.41) | CFBGMNNCYP1A2CYP3A4HTR1A | |
| SCHEMBL3414421 | 0.81 | TAAR1 (0.42) | CFBADRA2ACYP2D6ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2242753-B1 | OXAZOLIDINE AND THIAZOLIDINE SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-20140206701-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206701-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206701-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8735399-B2 | Selective subtype alpha 2 adrenergic agents and methods for use thereof | ALLERGAN, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735399-B2 | Selective subtype alpha 2 adrenergic agents and methods for use thereof | ALLERGAN, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735399-B2 | Selective subtype alpha 2 adrenergic agents and methods for use thereof | ALLERGAN, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8362022-B2 | Selective subtype alpha 2 adrenergic agents and methods for use thereof | ALLERGAN, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362022-B2 | Selective subtype alpha 2 adrenergic agents and methods for use thereof | ALLERGAN, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362022-B2 | Selective subtype alpha 2 adrenergic agents and methods for use thereof | ALLERGAN, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110105526-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. | 2011-05-05 | — | — | US | disclosed |
| US-20110105526-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. | 2011-05-05 | — | — | US | disclosed |
| US-20110105526-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. | 2011-05-05 | — | — | US | disclosed |
| US-20110034517-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034517-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034517-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| WO-2009091759-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009091760-A1 | OXAZOLIDINE AND THIAZOLIDINE SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206701-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ADRB2, ADRA2C, ADRA2A | KCNA5 635/4885CFB 4622/4885P2RX7 611/4885 |
| US-20110034517-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ADRB2, ADRA2C, ADRA2A | KCNA5 640/4885CFB 4625/4885P2RX7 556/4885 |
| US-20110105526-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ADRB2, ADRA2C, ADRA2A | KCNA5 953/4885CFB 4814/4885P2RX7 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.